8-K - Indaptus Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Indaptus Therapeutics announced the resignation of CFO Nir Sassi and appointed Qinglai Lu to the Board and Audit Committee and Yu Ding as CFO, effective in early April 2026.

Key Takeaways

1CFO Nir Sassi resigned on April 1, 2026, with no disclosed disagreement on company operations.

2Qinglai Lu was appointed to the Board and Audit Committee, effective April 8, 2026, and deemed independent by Nasdaq standards.

3Yu Ding was appointed as the new Chief Financial Officer, effective immediately on April 1, 2026.

4Matthew McMurdo resigned from the Audit Committee, with Jerome Jabbour also appointed to the committee.

Current Report Details

Event Type

Management Change

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** ** Resign

Management Change

Chief Financial Officer on April 1Company on any matter relating to the Company

9.01

.** **Financial Statements and Exhibits.** (d) Exhibits. | Exhibit Number | | Description | |---|---|---| | 104 | | Cover Page Interactive Data File | ** ** **S

Exhibits Only

Executive & Director Changes

Nir Sassi

Chief Financial Officer

Resignation

Effective: 2026-04-01

Not based on any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

Qinglai Lu

Member of the Board of Directors

Appointment

Effective: 2026-04-08

Yu Ding

Chief Financial Officer

Appointment

Effective: 2026-04-01

Matthew McMurdo

Member of the Audit Committee

Resignation

Effective: 2026-03-31

Exhibits (1)

8-K